Search Results


Your search for Anthony Zietman, MD matches 8 pages

Showing 1 - 8

Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASTRO’s Red Journal

The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...

Three Leaders in Radiation Oncology Awarded the ASTRO Gold Medal

Three leaders in radiation oncology have been named recipients of the American Society for Radiation Oncology (ASTRO) Gold Medal. Benedick A. Fraass, PhD, FASTRO; ­Christopher G. Willett, MD, FASTRO; and ­Anthony L. Zietman, MD, FASTRO; will be recognized at an awards ceremony during ­ASTRO’s 58th...

prostate cancer

Anthony Zietman, MD, on Accelerating Treatment: RTOG 0415 Study on Prostate Cancer

Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

prostate cancer

Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601

Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).

health-care policy

Rising Costs in Radiation Oncology Linked to Medicare Coverage

In the ongoing debate over how to control rising cancer care costs, it is vital to identify usage patterns of expensive new technologies. A recent study examined the relationship between Medicare reimbursement and the increasing use of intensity-modulated radiation therapy (IMRT).1 The ASCO Post...

prostate cancer

Prostatectomy vs Radiotherapy: A Study for Cautious Interpretation

Men with newly diagnosed localized prostate cancer face a decision between prostatectomy and radiotherapy, treatments deemed similarly effective but with well-established trade-offs in terms of treatment-related morbidity. Numerous clinical trials and other prospective studies, from both academic...

prostate cancer

Active Surveillance in Low-Risk Prostate Cancer: When Will We Pay It More Than Just Lip Service?

Active surveillance is well established as an appropriate management option for men with low-risk prostate cancer and particularly for those over 65 years of age. Its legitimacy is now enshrined within National Comprehensive Cancer Network guidelines, in the American Society for Radiation Oncology...

issues in oncology

New Techniques in Oncologic Surgery and Radiology: Some Worth the Expense, Some Not So Much

In recent years, patients with cancer have had the benefit of much high technology: proton-beam radiotherapy, intensity-modulated radiation therapy, various minimally invasive surgery techniques, and robots in the operating room. They all receive hype in the professional and public press, and...